Invyxis will add proven medicinal chemistry and comprehensive biological evaluation capabilities to grow atai’s portfolio of new chemical entities (NCEs) Early focus will be on designing unique, novel compounds aimed at the serotonin 5-HT2A receptor with other central nervous system (CNS) targets to follow This new platform company is a further step-up in atai’s commitment to next-generation…


Previous articleatai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
Next articleNova Mentis and KGK Science Form Tactical Partnership